Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its Investment First in Series of Anticipated Strategic Collaborations Designed to Further the Company's Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19 NEW BRUNSWICK, N.J.
- Sales of $20.7 billion reflecting strong growth of 3.3%, operational growth of 4.8%* and adjusted operational growth of 5.6%*, inclusive of the overall estimated negative impact of the COVID-19 pandemic - EPS of $2.17 increased 56.1%; adjusted EPS of $ 2.30 increased 9.5%* - Dividend increase of
NEW BRUNSWICK, N.J. , April 14, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. "In recognition of our 2019 results, strong financial position and
NEW BRUNSWICK, N.J. , April 1, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that, in light of the evolving situation with the coronavirus outbreak (COVID-19), it will reschedule its 2020 Medical Devices Business Review that was planned to take place on May 13, 2020 . Johnson
NEW BRUNSWICK, N.J. , March 31, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the 2020 Annual Meeting of Shareholders will now be conducted exclusively online by remote communication. This decision was made in light of the coronavirus outbreak ("COVID-19"), public health
Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson Will Establish New U.S.
